France's Pierre Fabre is enhancing its presence in the women's health market by taking a stake in dietary supplements and cosmetics firm MiYé.

A partnership with Swiss functional ingredients supplier Phytonet AG brings UK prebiotic specialist Clasado 14 steps closer to global coverage for Bimuno GOS. 

Cipla has signaled its commitment to expanding its OTC offering with the acquisition of South Africa's Actor Pharma and its diversified consumer health portfolio.

NBA star Antetokounmpo invests in Flexpower; Perrigo changes Americas helm; Bündchen models healthy lifestyle for Gaia; Vit-Best appoints growth chief; Olympian Jennings works with Protein Puck; and more.

The US FTC’s Sam Levine, director of the Bureau of Consumer Protection, discusses the advent of AI and the compounding risks consumers face in today’s evolving, largely unregulated, profoundly uncertain digital age.

Canadian firm launches US sales of Lumify Eye Illuminations 3-in-1 Micellar Cleansing Water and Eye Makeup Remover, Nourishing Lash & Brow Serum and Hydra-Gel Brightening Eye Cream. Each product contains hyaluronic acid, a fluid in eyes and joints which acts as a cushion and lubricant.

To counteract falling sales due to weaker immunity supplement demand post-pandemic, ingredients firm DSM-Firmenich is investing in innovation in the increasingly popular women's health and postbiotics product categories. 

Australian heritage dietary supplements brand Swisse achieved a significant sales milestone in the first half of 2023 reflecting growing demand for its products, particularly in China.

Germany's Dermapharm said strong global demand for dietary supplements, in combination with its acquisition of herbals specialist Arkopharma, had helped drive up sales in the first half of 2023.

“There is no bright-line requirement that a company possess randomized, controlled clinical studies before making so-called ‘health benefit’ claims for dietary supplements,” CRN states in petition. FTC, however, says it “makes no bright-line distinctions between categories of health-related products or claims.”

Trade group ask FTC to withdraw notices, arguing it is attempting to impose substantiation standard prohibited under FDA regulations for supplement manufacturing and marketing and are inconsistent with its own as well as FDA guidance

“The defendants’ argument rests on a misunderstanding of the basis for the contempt judgment” which were “imposed because the defendants violated the injunction,” says three-judge 11^th Circuit panel.